Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-γ activation

Protein and Peptide Letters

Volumn 15, Issue 8, 2008, Pages 850-853

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a   Nakamura, Kazuo ^a   Takeuchi, Masayoshi ^b   Inoue, Hiroyoshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; PPAR ; RAGE; Renin angiotensin system; Telmisartan

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

ADULT; ANIMAL; ARTICLE; CATTLE; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CATTLE; DOWN-REGULATION; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; PPAR GAMMA; RECEPTORS, IMMUNOLOGIC;

EID: 51449089179     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986608785203746     Document Type: Article

References (29)

1. Yamagishi, S. and Imaizumi, T. (2005) Curr. Pharm. Des., 11, 2279-2299.
2. The Diabetes Control and Complications Trial Research Group. (1993) N. Engl. J. Med., 329, 977-986.
3. UK Prospective Diabetes Study (UKPDS) Group. (1998) Lancet, 352, 837-853.
4. Brownlee, M., Cerami, A. and Vlassara, H. (1998) N. Engl. J. Med., 318, 1315-1321.
5. Vlassara, H. and Bucala, R. (1996) Diabetes Suppl., 3, S65-S66.
6. Hudson, B.I., Bucciarelli, L.G., Wendt, T., Sakaguchi, T., Lalla, E., Qu, W., Lu, Y., Lee, L., Stern, D.M., Naka, Y., Ramasamy, R., Yan, S.D., Yan, S.F., D'Agati, V. and Schmidt, A.M. (2003) Arch. Biochem. Biophys., 419, 80-88.
7. Schmidt, A.M., Yan, S.D., Yan, S.F. and Stern, D.M. (2000) Biochim. Biophys. Acta, 1498, 430-436.
8. Yamagishi, S., Takeuchi, M., Matsui, T., Nakamura, K., Imaizumi, T. and Inoue, H. (2005) FEBS Lett., 579, 4265-4270.
9. Yamagishi, S., Matsui, T., Nakamura, K., Takeuchi, M. and Imaizumi, T. (2006) Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc. Res., 72, 86-90.
10. Yamagishi, S., Nakamura, K., Matsui, T., Inagaki, Y., Takenaka, K., Jinnouchi, Y., Yoshida, Y., Matsuura, T., Narama, I,. Motomiya, Y., Takeuchi, M., Inoue, H., Yoshimura, A., Bucala, R. and Imaizumi, T. (2006) J. Biol. Chem., 281, 20213-20220.
11. Yamagishi, S., Amano, S., Inagaki, Y., Okamoto, T., Inoue, H., Takeuchi, M., Choei, H., Sasaki, N. and Kikuchi, S. (2003) Drugs Exp. Clin. Res., 29, 75-80.
12. Thomas, M.C., Tikellis, C., Burns, W.M., Bialkowski, K., Cao, Z., Coughlan, M.T., Jandeleit-Dahm, K., Cooper, M.E. and Forbes, J.M. (2005) J. Am. Soc. Nephrol., 16, 2976-2984.
13. Nakamura, K., Yamagishi, S., Nakamura, Y., Takenaka, K., Matsui, T., Jinnouchi, Y. and Imaizumi, T. (2005) Microvasc Res., 70, 137-141.
14. Fukami, K., Ueda, S., Yamagishi, S., Kato, S., Inagaki, Y., Takeuchi, M., Motomiya ,Y., Bucala, R., Iida, S., Tamaki, K., Imaizumi, T., Cooper, M.E. and Okuda, S. (2004) Kidney Int., 66, 2137-2147.
15. Yamagishi, S., Nakamura, K. and Matsui, T. (2007) Curr. Mol. Med., 7, 463-469.
16. Yoshida, T., Yamagishi, S., Nakamura, K., Matsui, T., Imaizumi, T., Takeuchi, M., Koga, H., Ueno, T. and Sata, M. (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia, 49, 3094-3099.
17. Yamagishi, S., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M. and Makita, Z. (2002) J. Biol. Chem., 277, 20309-20315.
18. Kurtz, T.W. (2005) Acta. Diabetol., 42, S9-S16.
19. Kintscher, U. and Unger, T. (2005) Acta. Diabetol., 42, S26-S32.
20. Yamagishi, S. and Takeuchi, M. (2005) Med. Hypothese., 64, 476-478.
21. Marx, N., Walcher, D., Ivanova, N., Rautzenberg, K., Jung, A., Friedl, R., Hombach, V., de Caterina, R., Besta, G., Wautier, M.P. and Wautiers, J.L. (2004) Diabetes, 53, 2662-2668.
22. Mamputu, J,C. and Renier, G. (2004) J. Leukoc. Biol., 75, 1062-1069.
23. Miyamoto, K., Khosrof, S., Bursell, S.E., Rohan, R., Murata, T., Clermont, A.C., Aiello, L.P., Ogura, Y. and Adamis, A.P. (1999) Proc. Natl. Acad. Sci. USA, 96, 10836-10841.
24. Matsumoto, Y., Takahashi, M. and Ogata, M. (2002) Jpn. J. Ophthalmol., 46, 406-412.
25. Okamoto, T., Yamagishi, S., Inagaki, Y., Amano, S., Koga, K., Abe, R., Takeuchi, M., Ohno, S., Yoshimura, A. and Makita, Z. (2002) FASEB J., 16, 1928-1930.
26. Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., Atkins, R.C., Rollin, B.J. and Tesch, G.H. (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int., 69, 73-80.
27. Okada, S., Shikata, K., Matsuda, M., Ogawa, D., Usui, H., Kido, Y., Nagase, R., Wada, J., Shikata, Y. and Makino, H. (2003) Diabetes, 52, 2586-2593.
28. de Vriese, A.S., Tilton, R.G., Elger, M., Stephan, C.C., Kriz, W. and Lameire, N.H. (2001) J. Am. Soc. Nephrol., 12, 993-1000.
29. Flyvbjerg, A., Dagnaes-Hansen, F., De Vriese, A.S., Schrijvers, B.F., Tilton, R.G. and Rasch, R. (2002) Diabetes, 51, 3090-3094.